Full Press Release Details
Comparison of the Three Months Ended September 30, 2023 and 2024
following table presents OSR Holdings's statement of operations data for the three months ended September 30, 2023 and 2024, and
the Korean won (KRW) and percentage change between the two periods:
| Three Months Ended September 30, (Korean Won in thousands) | ||||||||||||||||
| 2023 | 2024 | Change $ | Change % | |||||||||||||
| (Unaudited) | ||||||||||||||||
| Net Sales: | 1,154,906 | 1,119,394 | (35,512 | ) | -3 | % | ||||||||||
| Cost of Sales | 1,008,956 | 875,526 | (133,430 | ) | -13 | % | ||||||||||
| Gross Profit | 145,950 | 243,868 | 97,918 | 67 | % | |||||||||||
| Selling, general and administrative expenses | (6,805,411 | ) | (5,090,682 | ) | 1,714,729 | -25 | % | |||||||||
| Operating loss | (6,659,461 | ) | (4,846,814 | ) | 1,812,647 | -27 | % | |||||||||
| Other income (expense) | (111,995 | ) | 94,992 | 206,987 | -185 | % | ||||||||||
| Loss before income taxes | (6,771,456 | ) | (4,751,822 | ) | 2,019,634 | -30 | % |
Net sales decreased by KRW 36 million reflecting
a decline in net sales of OSR's portfolio company, RMC, due primarily to the termination of RMC's distribution agreement with
Penumbra for its neuro intervention medical device equipment. OSR expects its revenue to decrease in 2025 and possibly longer, until RMC
can replace sales of Penumbra's products by increasing sales or incorporating additional products from other manufacturers.
Cost of Sales and Gross Margin
Cost of sales decreased by KRW 133 million,
or 13%, due to the decline in sales with the termination of RMC's distribution agreement with Penumbra, which resulted in lower
purchase volumes from Penumbra. Gross profit increased by KRW 98 million, or 67%, from KRW 146 million to KRW 244 million, primarily due
to increased sales of higher margin products.
Research and Development Expenses
Research and development expenses increased by KRW
56 million, or 308%, from KRW 18 million for the three months ended September 30, 2023 to KRW 74 million for the three months ended September
30, 2024. This was primarily due to increased spending by Darnatein on research and development expenses.
Selling, General, and Administrative Expenses
SG&A expenses decreased by KRW 1,715 million,
or 25%, from KRW 6,805 million for the three months ended September 30, 2023, to KRW 5,091 million for the three months
ended September 30, 2024. The decrease was primarily attributable to a reduction in amortization expense (KRW 1,859 million), caused
by change in assumption used in amortization method, offset to a lesser extent by increases in building maintenance expense (KRW 227 million)
and the increase in research and development expenses.
Other Income (Expense)
Other income increased by KRW 207 million, from
a loss of KRW 112 million in the third quarter of 2023, to income of KRW 95 million in the third quarter of 2024. The increase is primarily
attributable to reducing the loss on foreign currency translation, from KRW 257 million to KRW 39.9 million.
Loss Before Income Taxes
Loss before income taxes for the Quarter was reduced
by KRW 682 million, or 30%, from 6.8 billion for the three months ended September 30, 2023 to KRW 4.8 billion for
the three months ended September 30, 2024, reflecting primarily a reduction in SG&A expenses and to a lesser extent, a reduction in
Comparison of the Nine Months Ended September 30, 2023 and 2024
following table presents OSR's statement of operations data for the nine months ended September 30, 2023 and 2024, and the Korean
won (KRW) and percentage change between the two periods:
| Nine Months Ended September 30, (Korean Won in thousands) | ||||||||||||||||
| 2023 | 2024 | Change $ | Change % | |||||||||||||
| (Unaudited) | ||||||||||||||||
| Net Sales: | 3,139,754 | 3,537,771 | 398,017 | 13 | % | |||||||||||
| Cost of Sales | 2,269,583 | 2,656,774 | 387,191 | 17 | % | |||||||||||
| Gross Profit | 870,171 | 880,997 | 10,826 | 1 | % | |||||||||||
| Selling, general and administrative expenses | (12,345,574 | ) | (14,516,613 | ) | (2,171,039 | ) | 18 | % | ||||||||
| Operating loss | (11,475,402 | ) | (13,635,616 | ) | (2,160,214 | ) | 19 | % | ||||||||
| Other income (expense) | (398,126 | ) | (31,646 | ) | 366,480 | -92 | % | |||||||||
| Loss before income taxes | (11,873,528 | ) | (13,667,262 | ) | (1,793,734 | ) | 15 | % |
Net sales increased by KRW 398 million, or 13%,
reflecting an increase in net sales of OSR's portfolio company, RMC, due primarily to its expansion of sales product portfolio.
Although sales increased in the nine-month period, with the termination of RMC's contract with Penumbra, OSR expects its revenue
to decrease in 2025 and possibly longer, until RMC can replace sales of Penumbra's products by increasing sales or incorporating
additional products from other manufacturers.
Cost of Sales and Gross Margin
Cost of sales increased by KRW 387 million,
or 17%, reflecting almost entirely the increase in sales volumes for RMC, which purchases products from its suppliers for resale (so,
as sales increase, cost of sales increases). Gross profit increased by approximately KRW 11 million, or 1.2%. Gross margin percentage
decreased from 27.7% to 24.9%, primarily due to reduced service revenue of Vaximm.
Research and Development Expenses
Research and development expenses remained essentially
flat for the two periods, at KRW 198 million for the nine-months ended September 30, 2023 and September 30, 2024. OSR Holdings expects
research and development expenses to increase in 2025 if its cash position improves following the completion by BLAC of the acquisition
Selling, General, and Administrative Expenses
SG&A expenses increased by KRW 2.2 billion,
or 18%, from KRW 12.3 billion for the nine- months ended September 30, 2023, to KRW 14.5 billion for the nine-months ended September 30,
2024. The increase was primarily attributable to the increase in amortization expenses, which increased by KRW 1.9 billion, or 19%, and
to a lesser extent, commissions and professional fees, which increased by KRW 269 million or 26%, and wages and salaries, which increased
by KRW 124 million, or 15%.
Other Income (Expense)
Interest income decreased from KRW 30 million
in the nine-months ending September 30, 2023 to KRW 15 million in the nine-months ending September 30, 2024, a decline of 50%. Interest
expense decreased by KRW 407 million, or 92%, from KRW 440 million to KRW 33 million as a result of reduction in outstanding
debt of OSR Holdings and its subsidiaries. Other income (gains on foreign currency exchange and foreign currency translation) decreased
by KRW 239 million, from KRW 369 million to KRW 130 million. Other expenses decreased by KRW 214 million, from KRW
358 million to KRW 143 million (losses on foreign currency translation and foreign currency exchange).
Loss Before Income Taxes
Loss before income taxes for the Nine Months
Ending September 30, 2024 increased by KRW 1.9 billion, or 15%, from 11.9 billion for the nine months ended September 30,
2023 to KRW 13.7 billion for the nine-months ended September 30, 2024, reflecting higher SG&A expenses, and, to a lesser extent,
reduced gross profits from operations.
Comparison of the Years Ended December 31, 2022 and
The following table presents OSR Holdings'
statements of operations for the years ended December 31, 2022 and 2023, and the Korean won (KRW) and percentage change
between the two years:
| Year Ended December 31, (Korean won in thousands) | ||||||||||||||||
| 2022 | 2023 | Change $ | Change % | |||||||||||||
| Net Sales: | 8,758 | 4,453,551 | 4,444,793 | 50,751 | % | |||||||||||
| Cost of Sales | - | 3,278,703 | 3,278,703 | |||||||||||||
| Gross Profit | 8,758 | 1,174,848 | 1,166,090 | 13,315 | % | |||||||||||
| Selling, general and administrative expenses | (1,339,669 | ) | (15,955,519 | ) | (14,615,850 | ) | 1,091 | % | ||||||||
| Operating loss | (1,330,911 | ) | (14,780,671 | ) | (13,449,760 | ) | 1,011 | % | ||||||||
| Other income (expense) | 2,119,106 | (956,445 | ) | (3,075,551 | ) | -145 | % | |||||||||
| Loss before income taxes | 788,196 | (15,737,116 | ) | (16,525,312 | ) | -2,097 | % |
Net sales was KRW 4.5 billion, consisting of
sales of medical devices by OSR Holdings's RMC subsidiary in South Korea, which was acquired by OSR Holdings in late December 2022.
OSR Holdings had non-operating income in 2022 from a one-time gain on the disposition of certain financial assets, as described below.
Cost of sales was KRW 3.3 billion in 2023,
consisting of costs of medical devices purchased (for resale) by OSR Holdings's RMC subsidiary in South Korea.
Gross profit was KRW 1.2 billion in 2023 from
the sales of medical devices by OSR Holdings's RMC subsidiary in South Korea.
Selling, General and Administrative Expenses
SG&A expenses consist of personnel-related expenses,
including salaries, benefits, bonus, and travel. Other SG&A expenses include amortization of intangible assets, research and development
expenses, professional services fees, such as legal, audit, and investor/press relations, research and development expenses, non-income taxes,
insurance costs, cost of outside consultants and employee recruiting and training costs. SG&A expenses increased 1,091% in 2023, primarily
as a result of the amortization of acquired patents (84%) and consolidation of expenses acquired by subsidiaries (16%) which were not
reflected in 2022 financial results. Moreover, OSR Holdings expects to incur additional expenses associated with operating as a public
company, including legal, accounting, insurance, exchange listing and SEC compliance and investor relations. OSR Holdings expects quarterly
selling, general and administrative expenses, excluding stock compensation expense, to increase to an average of approximately $1.5 million per
quarter through the end of 2025.
Research and Development (R&D) Expenses
R&D expenses consist primarily of costs incurred
for research activities, including the development of product candidates, pre-clinical and clinical trials and related costs of salaries
and contractors. R&D costs are expensed as incurred. OSR Holdings R&D expenses for 2022 and 2023 were KRW 244 million and KRW
324 million, which came from the fully consolidated subsidiaries. OSR Holdings expects to incur and report R&D related expenses
mainly from its subsidiaries and affiliates actively engaged in R&D at an estimated amount of $2.5 million to $3.0 million
per quarter beginning in 2025.
Other Income (Expense)
Interest income increased from KRW 3 million
in 2022 to KRW 23 million in 2023, an increase of 704%. Interest expense increased by KRW 437 million, or 2,570%, from KRW 17 million
to KRW 454 million. Other income decreased by KRW 2.2 billion, from KRW 2.3 billion to KRW 160 million, primarily